Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China

Péter Boldog, Tamás Tekeli, Zsolt Vizi, Attila Dénes, Ferenc A. Bartha, Gergely Röst
doi: https://doi.org/10.1101/2020.02.04.20020503
Péter Boldog
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamás Tekeli
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zsolt Vizi
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Attila Dénes
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: denesa@math.u-szeged.hu
Ferenc A. Bartha
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gergely Röst
1Bolyai Institute, University of Szeged, H-6720 Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We developed a computational tool to assess the risks of novel coronavirus outbreaks outside of China. We estimate the dependence of the risk of a major outbreak in a country from imported cases on key parameters such as: (i) the evolution of the cumulative number of cases in mainland China outside the closed areas; (ii) the connectivity of the destination country with China, including baseline travel frequencies, the effect of travel restrictions, and the efficacy of entry screening at destination; and (iii) the efficacy of control measures in the destination country (expressed by the local reproduction number Rloc). We found that in countries with low connectivity to China but with relatively high Rloc, the most beneficial control measure to reduce the risk of outbreaks is a further reduction in their importation number either by entry screening or travel restrictions. Countries with high connectivity but low Rloc benefit the most from policies that further reduce Rloc. Countries in the middle should consider a combination of such policies. Risk assessments were illustrated for selected groups of countries from America, Asia, and Europe. We investigated how their risks depend on those parameters, and how the risk is increasing in time as the number of cases in China is growing.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

G.R. was supported by EFOP-3.6.1-16-2016-00008. F.B. was supported by NKFIH KKP 129877. T.T. was supported by NKFI FK 124016, A.D. was supported by NKFIH PD 128363 and by the J\'anos Bolyai Research Scholarship of the Hungarian Academy of Sciences. P.B. was supported by 20391-3/2018/FEKUSTRAT.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • boldogpeter{at}gmail.com (P.B.); tekeli.tamas{at}gmail.com (T.T.); zsvizi{at}math.u-szeged.hu (Z.V.); barfer{at}math.u-szeged.hu (F.A.B.); rost{at}math.u-szeged.hu (G.R.)

Data Availability

Links to all data used in the manuscript are provided.

http://www.epirisk.net

https://docs.google.com/spreadsheets/d/1wQVypefm946ch4XDp37uZ-wartW4V7ILdg-qYiDXUHM/htmlview?usp=sharing&sle=true

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 27, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China
Péter Boldog, Tamás Tekeli, Zsolt Vizi, Attila Dénes, Ferenc A. Bartha, Gergely Röst
medRxiv 2020.02.04.20020503; doi: https://doi.org/10.1101/2020.02.04.20020503
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China
Péter Boldog, Tamás Tekeli, Zsolt Vizi, Attila Dénes, Ferenc A. Bartha, Gergely Röst
medRxiv 2020.02.04.20020503; doi: https://doi.org/10.1101/2020.02.04.20020503

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)